Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma
Sign Up to like & getrecommendations! Published in 2025 at "Leukemia"
DOI: 10.1038/s41375-025-02757-6
Abstract: Introduction: Despite potent efficacy of bispecific antibodies against the B-cell maturation antigen (BCMA) in multiple myeloma (MM), primary resistance may occur in as many as 40% of patients. Known resistance mechanisms include antigen loss, epigenetic… read more here.
Keywords: bcma; anti bcma; sbcma; plasmapheresis ... See more keywords
A-141 Biological variation of soluble B-cell maturation antigen in healthy donors
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Chemistry"
DOI: 10.1093/clinchem/hvaf086.137
Abstract: B-cell maturation antigen (BCMA) is a receptor involved in the development and function of B-cells, primarily expressed on plasma cells and some mature B-cells. The soluble form of BCMA (sBCMA) is detectable in peripheral blood… read more here.
Keywords: cell maturation; chemistry; healthy donors; sbcma ... See more keywords
Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "Neuro-Oncology"
DOI: 10.1093/neuonc/nox097
Abstract: Background B-cell survival is regulated through interactions of B-cell-activating factor and a proliferation-inducing ligand with their receptors transmembrane activator and CAML interactor (TACI) and B-cell maturation antigen (BCMA). We evaluated the diagnostic potential of soluble… read more here.
Keywords: soluble bcma; soluble taci; bcma; sbcma ... See more keywords
Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-132012
Abstract: Introduction: B-cell maturation antigen (BCMA) is a protein that is expressed on malignant plasma cells from patients (pts) with multiple myeloma (MM). Our group has previously shown that MM pts have higher levels of serum… read more here.
Keywords: protein; pfs; sbcma; cycle ... See more keywords
Combining Gene Expression Profiling and Integrated Multidisciplinary Approaches to Improve Prognosis Prediction in Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-203211
Abstract: Introduction: Despite the therapeutic advancements in the treatment of multiple myeloma (MM), particularly in the frontline setting where monoclonal antibodies anti-CD38 have become a backbone, a subset of patients continue to show early relapse and… read more here.
Keywords: sbcma; risk; smm; ndmm rrmm ... See more keywords
Integrated multidisciplinary approaches to improve prognosis prediction in multiple myeloma
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-2140
Abstract: Introduction: Despite the therapeutic advancements in the treatment of multiple myeloma (MM) a subset of patients shows dismal prognosis. Biomarkers of high-risk (HR) and multiomics-based techniques are in continuous implementation to intercept HR patients at… read more here.
Keywords: multiple myeloma; sbcma; prognosis; ndmm rrmm ... See more keywords
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007625
Abstract: B-cell maturation antigen (BCMA) is selectively expressed as a surface protein on plasma cells and is a validated target for multiple myeloma (MM). A soluble form of BCMA (sBCMA) is elevated in the sera of… read more here.
Keywords: sbcma levels; sbcma; bcma; talquetamab ... See more keywords
Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.8047
Abstract: 8047 Background: B-cell maturation antigen (BCMA, CD269) is a single transmembrane protein that is selectively expressed in the B-cell lineage and is a validated target for multiple myeloma. BCMA exists as both surface protein and… read more here.
Keywords: sbcma; teclistamab; teclistamab talquetamab; multiple myeloma ... See more keywords
Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.7532
Abstract: 7532 Background: ABBV-383 is a BCMA x CD3 bispecific antibody with 2 high-affinity BCMA-binding domains and a low-affinity CD3 engaging arm that has been shown to decrease the negative impact of soluble BCMA (sBCMA) and… read more here.
Keywords: dose; bcma; abbv 383; sbcma ... See more keywords